美国社区肿瘤诊疗环境中接受PARP抑制剂维持治疗的卵巢癌患者的医疗服务利用情况
该回顾性研究纳入2017年1月1日至2019年6月30日启动PARP抑制剂单药维持治疗的162例卵巢癌患者,随访至2019年12月31日,描述治疗模式与医疗资源利用。尼拉帕利组剂量中断和毒性停药比例较高,但门诊和实验室利用在三药间相似,住院和急诊就诊比例存在差异。
要点
- 尼拉帕利、瑞卡帕利、奥拉帕利组剂量中断比例分别为51%、50%、28%,毒性停药分别为37%、17%、15%。
- 前6个月尼拉帕利、瑞卡帕利、奥拉帕利组总索赔均值分别为43.5、56.4、36.0,实验室索赔分别为13.9、19.4、15.6。
- 住院比例尼拉帕利40%、瑞卡帕利32%、奥拉帕利19%(p=0.03),急诊就诊分别为37%、23%、16%(p=0.02)。
核心结论
- 尽管尼拉帕利组剂量管理事件和毒性相关停药率较高,三种PARP抑制剂的门诊和实验室利用相似;应强调充分监测以潜在减少剂量调整和毒性。
研究设计与样本
- 回顾性研究,纳入2017年1月1日至2019年6月30日启动PARP抑制剂单药维持治疗的卵巢癌患者,随访至2019年12月31日,共回顾162份病历。
- 纳入标准为首次诊断卵巢癌时年龄≥18岁且在美国肿瘤网络内至少有2次就诊。
- 使用结构化数据、病历回顾数据和索赔数据描述治疗模式和医疗资源利用。
主要发现
- 患者中位年龄66岁,80%诊断时为III或IV期。
- 尼拉帕利、瑞卡帕利、奥拉帕利组剂量中断比例分别为51%、50%、28%,毒性相关停药比例分别为37%、17%、15%。
- 前6个月内,尼拉帕利、瑞卡帕利、奥拉帕利组总索赔均值分别为43.5、56.4、36.0,实验室索赔均值分别为13.9、19.4、15.6。
- 住院比例尼拉帕利40%、瑞卡帕利32%、奥拉帕利19%(p=0.03);急诊就诊比例尼拉帕利37%、瑞卡帕利23%、奥拉帕利16%(p=0.02)。
临床怎么用
- 作者认为,应强调对这些毒性不同的药物进行充分监测,以潜在减少剂量调整和毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to describe healthcare resource use (HCRU) in addition to treatment patterns and discontinuations, in patients with ovarian cancer (OC) initiating PARP inhibitor (PARPi) maintenance treatment in a US community oncology setting. METHODS: This was a retrospective study of patients with OC initiating PARPi monotherapy maintenance during 01/01/2017 to 06/30/2019 (followed until 12/31/2019). Patients aged ≥18 years at first diagnosis of OC with ≥2 visits within The US Oncology Network were included. Structured and chart review data as well as claims data were used to describe treatment patterns and HCRU. RESULTS: Of the 162 charts reviewed, the median age of patients was 66 years and 80% had stage III or IV disease at diagnosis. In the niraparib, rucaparib and olaparib groups, proportions of patients experiencing dose interruptions were 51%, 50%, and 28%, and discontinuations due to toxicity were 37%, 17% and 15%, respectively. Within the first 6 months, mean numbers of total claims were 43.5, 56.4, and 36.0 in the niraparib, rucaparib, and olaparib groups, and laboratory claims were 13.9, 19.4, and 15.6, respectively. Proportions of patients with hospitalizations (niraparib 40%, rucaparib 32%, olaparib 19%; p = 0.03), also differed as did emergency department visits (niraparib 37%, rucaparib 23%, olaparib 16%; p = 0.02). CONCLUSION: Despite patients initiating niraparib having higher rates of dose management events and toxicity-related discontinuations, outpatient and laboratory utilization were similar across all three PARPi. Adequate monitoring of these medications, with differing toxicities, should be emphasized to potentially decrease dose reductions and toxicities.
引用
- Chase DM, Annavarapu S, Tseng WY, et al. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting. Gynecol Oncol. 2023. PMID: 38056115. doi:10.1016/j.ygyno.2023.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。